1
|
Duque-Quintero M, Hooijmans CR, Hurowitz A, Ahmed A, Barris B, Homberg JR, Hen R, Harris AZ, Balsam P, Atsak P. Enduring effects of early-life adversity on reward processes: A systematic review and meta-analysis of animal studies. Neurosci Biobehav Rev 2022; 142:104849. [PMID: 36116576 PMCID: PMC10729999 DOI: 10.1016/j.neubiorev.2022.104849] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Revised: 08/23/2022] [Accepted: 08/26/2022] [Indexed: 01/06/2023]
Abstract
Two-thirds of individuals experience adversity during childhood such as neglect, abuse or highly-stressful events. Early-life adversity (ELA) increases the life-long risk of developing mood and substance use disorders. Reward-related deficits has emerged as a key endophenotype of such psychiatric disorders. Animal models are invaluable for studying how ELA leads to reward deficits. However, the existing literature is heterogenous with difficult to reconcile findings. To create an overview, we conducted a systematic review containing multiple meta-analyses regarding the effects of ELA on reward processes overall and on specific aspects of reward processing in animal models. A comprehensive search identified 120 studies. Most studies omitted key details resulting in unclear risk of bias. Overall meta-analysis showed that ELA significantly reduced reward behaviors (SMD: -0.42 [-0.60; -0.24]). The magnitude of ELA effects significantly increased with longer exposure. When reward domains were analyzed separately, ELA only significantly dampened reward responsiveness (SMD: -0.525[-0.786; -0.264]) and social reward processing (SMD: -0.374 [-0.663; -0.084]), suggesting that ELA might lead to deficits in specific reward domains.
Collapse
Affiliation(s)
- Mariana Duque-Quintero
- Department of Cognitive Neuroscience, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands; Donders Institute for Brain, Cognition and Behaviour, Radboud University, 6525 EN Nijmegen, The Netherlands
| | - Carlijn R Hooijmans
- Systematic Review Centre for Laboratory animal Experimentation (SYRCLE), Department for Health Evidence, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands; Department of Anesthesiology, Pain and Palliative Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
| | - Alexander Hurowitz
- Integrative Neuroscience, New York State Psychiatric Institute, New York 10032, USA
| | - Afsana Ahmed
- Integrative Neuroscience, New York State Psychiatric Institute, New York 10032, USA
| | - Ben Barris
- Integrative Neuroscience, New York State Psychiatric Institute, New York 10032, USA
| | - Judith R Homberg
- Department of Cognitive Neuroscience, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands; Donders Institute for Brain, Cognition and Behaviour, Radboud University, 6525 EN Nijmegen, The Netherlands
| | - Rene Hen
- Integrative Neuroscience, New York State Psychiatric Institute, New York 10032, USA; Department of Psychiatry, Columbia University, New York, NY 10032, USA
| | - Alexander Z Harris
- Integrative Neuroscience, New York State Psychiatric Institute, New York 10032, USA; Department of Psychiatry, Columbia University, New York, NY 10032, USA
| | - Peter Balsam
- Department of Psychiatry, Columbia University, New York, NY 10032, USA
| | - Piray Atsak
- Department of Cognitive Neuroscience, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands; Donders Institute for Brain, Cognition and Behaviour, Radboud University, 6525 EN Nijmegen, The Netherlands; Integrative Neuroscience, New York State Psychiatric Institute, New York 10032, USA; Department of Psychiatry, Columbia University, New York, NY 10032, USA.
| |
Collapse
|
2
|
Rickels K, Brown AS, Cohen D, Harris H, Hurowitz A, Lindenbaum EJ, Ross HA, Weinstock R, Wiseman K, Zal M. Clobazam and diazepam in anxiety. Clin Pharmacol Ther 1981; 30:95-100. [PMID: 6113074 DOI: 10.1038/clpt.1981.132] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The anxiolytic effects of clobazam, diazepam, and placebo were compared in a 4-wk double-blind study of 159 anxious outpatients, primarily from family practice. Clobazam (30 to 80 mg/day) and diazepam (15 to 40 mg/day) were found to induce similar side effect, primarily sedation, and although both active drugs induced greater clinical improvement than placebo, clobazam induced the largest degree of improvement in most aspects. It was speculated that the relatively high daily dosage of diazepam may have been contributed to these results.
Collapse
|